Abstract
Hypertension is one of the major causes of cardiovascular morbidity. Most patients who are on treatment for hypertension fail to achieve adequate control with the existing therapy and rates of cardiovascular morbidity remain high. As the renin-angiotensin-aldosterone system is strongly implicated in the development of hypertension-related target organ damage, intensive efforts have been devoted towards the development of drugs targeting this system. In addition to angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), inhibition of renin has also become a clinical reality. Aliskiren, a novel renin inhibitor, has overcome a number of shortcomings of existing drugs and is now available to address angiotensin production directly at its rate-limiting step.
Keywords: Renin inhibitor, SPP100, aliskiren, hypertension
Current Drug Therapy
Title: Aliskiren: A Novel Renin Inhibitor for Hypertension
Volume: 2 Issue: 3
Author(s): Vandana Tayal and Bhupinder Singh Kalra
Affiliation:
Keywords: Renin inhibitor, SPP100, aliskiren, hypertension
Abstract: Hypertension is one of the major causes of cardiovascular morbidity. Most patients who are on treatment for hypertension fail to achieve adequate control with the existing therapy and rates of cardiovascular morbidity remain high. As the renin-angiotensin-aldosterone system is strongly implicated in the development of hypertension-related target organ damage, intensive efforts have been devoted towards the development of drugs targeting this system. In addition to angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), inhibition of renin has also become a clinical reality. Aliskiren, a novel renin inhibitor, has overcome a number of shortcomings of existing drugs and is now available to address angiotensin production directly at its rate-limiting step.
Export Options
About this article
Cite this article as:
Tayal Vandana and Kalra Singh Bhupinder, Aliskiren: A Novel Renin Inhibitor for Hypertension, Current Drug Therapy 2007; 2 (3) . https://dx.doi.org/10.2174/157488507781695667
DOI https://dx.doi.org/10.2174/157488507781695667 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Origin of Chiral Pharmacology Stereochemistry in Metalloprotease Inhibition
Mini-Reviews in Medicinal Chemistry Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?
Current Pharmaceutical Biotechnology Hypoglycemia Induces Tau Hyperphosphorylation
Current Alzheimer Research Bronchopulmonary Dysplasia: An Imbalance of Inflammation
Current Respiratory Medicine Reviews Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry Motion Analysis of the Carotid Artery Wall and Plaque Using B-Mode Ultrasound
Vascular Disease Prevention (Discontinued) Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations
Current Rheumatology Reviews Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design The Heat Shock Connection of Metabolic Stress and Dietary Restriction
Current Pharmaceutical Biotechnology Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
Current Medicinal Chemistry Postmenopausal Hypertension: Insights from Rat Models
Current Hypertension Reviews Role of Polyunsaturated Fatty Acids and Fatty Acid Binding Protein in the Pathogenesis of Schizophrenia
Current Pharmaceutical Design Metabolic Syndrome, its Pathophysiology and the Role of Melatonin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Vasodilator Effects of Bis-Dihydropyridines Structurally Related to Nifedipine
Medicinal Chemistry Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology New Advances in Blockade of the Renin-Angiotensin System – the Role of Direct Renin Inhibition
Current Hypertension Reviews The Interplay Between Asthma and Other Diseases: Role of Ca2+/cAMP Signalling
Endocrine, Metabolic & Immune Disorders - Drug Targets